Literature DB >> 21828932

Impaired mobilization of CD133(+) bone marrow-derived circulating progenitor cells with an increased number of diseased coronary arteries in ischemic heart disease patients with diabetes.

R Goekmen Turan1, C Hakan Turan, Ilkay Bozdag-Turan, Jasmin Ortak, Ibrahim Akin, Stephan Kische, Henrik Schneider, Tilo Kleinfeldt, Tim C Rehders, Mathias Rauchhaus, Esther Adolph, Shwan Amen, Tina Hermann, Sedat Yokus, Micheal Brehm, Stephan Steiner, Kurtulus Sahin, Christoph A Nienaber, Hueseyin Ince.   

Abstract

BACKGROUND: The influence of the number of diseased coronary arteries on the mobilization of CD133/45(+) bone marrow-derived circulating progenitor cells (BM-CPCs) in peripheral blood (PB) in patients with ischemic heart disease (IHD) was analyzed. METHODS AND
RESULTS: Mobilization of CD133/45(+) BM-CPCs by flow cytometry was measured in 120 patients with coronary 1 vessel (IHD1, n=40), coronary 2 vessel (IHD2, n=40), and coronary 3 vessel disease (IHD3, n=40), and in a control group (n=40). The mobilization of CD133/45(+) BM-CPCs was significantly reduced in patients with IHD compared to the control group (P<0.001). The mobilization of CD133/45(+) BM-CPCs was impaired in patients with IHD3 compared to IHD1 (P<0.001) and to IHD2 (P<0.001). But there was no significant difference in mobilization of CD133/45(+) BM-CPCs between the patients with IHD2 and IHD1 (P=0.35). Moreover, we found significantly reduced CD133/45(+) cell mobilization in patients with a high SYNTAX-Score (SS) compared to a low SS (P<0.001) and an intermediate SS (P<0.001). In subgroup analyzes, we observed a significantly negative correlation between levels of hemoglobin A(1c) and the mobilization of CD133/45(+) BM-CPCs (P=0.001, r=-0.6).
CONCLUSIONS: The mobilization of CD133/45(+) BM-CPCs in PB is impaired in patients with IHD. This impairment might augment with increased number of diseased coronary arteries. Moreover, mobilization of CD133/45(+) BM-CPCs in ischemic tissue is further impaired by diabetes in patients with IHD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21828932     DOI: 10.1253/circj.cj-10-1284

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  5 in total

1.  A novel autologous cell-based therapy to promote diabetic wound healing.

Authors:  Diego M Castilla; Zhao-Jun Liu; Runxia Tian; Yan Li; Alan S Livingstone; Omaida C Velazquez
Journal:  Ann Surg       Date:  2012-10       Impact factor: 12.969

2.  Correlation between the functional impairment of bone marrow-derived circulating progenitor cells and the extend of coronary artery disease.

Authors:  Ilkay Bozdag-Turan; R Goekmen Turan; Lylia Paranskaya; Nicole S Arsoy; C Hakan Turan; Ibrahim Akin; Stephan Kische; Jasmin Ortak; H Schneider; S Ludovicy; Tina Hermann; Giuseppe D'Ancona; Serkan Durdu; A Ruchan Akar; Hueseyin Ince; Christoph A Nienaber
Journal:  J Transl Med       Date:  2012-07-09       Impact factor: 5.531

3.  Number and function of bone-marrow derived angiogenic cells and coronary flow reserve in women without obstructive coronary artery disease: a substudy of the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE).

Authors:  Rajesh Mohandas; Larysa Sautina; Shiyu Li; Xuerong Wen; Tianyao Huo; Eileen Handberg; Yueh-Yun Chi; C Noel Bairey Merz; Carl J Pepine; Mark S Segal
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

4.  Increased circulating endothelial apoptotic microparticle to endothelial progenitor cell ratio is associated with subsequent decline in glomerular filtration rate in hypertensive patients.

Authors:  Chien-Yi Hsu; Po-Hsun Huang; Chia-Hung Chiang; Hsin-Bang Leu; Chin-Chou Huang; Jaw-Wen Chen; Shing-Jong Lin
Journal:  PLoS One       Date:  2013-07-12       Impact factor: 3.240

Review 5.  Bone Marrow-Derived Stem Cells: a Mixed Blessing in the Multifaceted World of Diabetic Complications.

Authors:  Giuseppe Mangialardi; Paolo Madeddu
Journal:  Curr Diab Rep       Date:  2016-05       Impact factor: 4.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.